The best indicator for Amphenol (APH)
We backtested 20 indicators across daily, weekly and hourly charts on real Amphenol (APH) history. Here's what actually worked — risk-adjusted, out-of-sample, with costs.
RSI Trend (>50)
On the weekly chart, this is the strongest risk-adjusted edge we found for Amphenol (APH) over ~34.7 years — trailing buy-and-hold by 7.9% CAGR.
The winner on each chart
Every indicator, ranked
Ranked by Sharpe (risk-adjusted return). Hypothetical, fees included.
| # | Indicator | TF | CAGR | Sharpe | Max DD | Win | Trades | vs B&H |
|---|---|---|---|---|---|---|---|---|
| 1 | RSI Trend (>50) ✓ | Weekly | 14.5% | 0.66 | -58.6% | 47.6% | 84 | -7.9% |
| 2 | Donchian Midline ✓ | Weekly | 14.4% | 0.66 | -65.1% | 52.8% | 89 | -8.0% |
| 3 | EMA 50/200 Cross ✓ | Daily | 15.1% | 0.64 | -71.1% | 47.4% | 19 | -7.4% |
| 4 | SMA 50/200 Cross ✓ | Daily | 14.3% | 0.61 | -62.8% | 70.0% | 20 | -8.2% |
| 5 | EMA 20/50 Cross ✓ | Daily | 12.4% | 0.58 | -73.7% | 42.7% | 75 | -10.1% |
| 6 | WaveTrend (8/6/4) ✓ | Daily | 12.0% | 0.57 | -62.7% | 74.8% | 131 | -10.5% |
| 7 | ADX / DMI ✓ | Weekly | 10.8% | 0.57 | -45.7% | 42.6% | 54 | -11.5% |
| 8 | EMA-10 Trend ✓ | Weekly | 11.4% | 0.57 | -51.6% | 46.7% | 152 | -11.0% |
| 9 | Rate of Change ✓ | Daily | 11.3% | 0.56 | -52.1% | 45.9% | 525 | -11.2% |
| 10 | MACD ✓ | Daily | 10.9% | 0.55 | -44.5% | 45.9% | 333 | -11.6% |
| 11 | RSI Trend (>50) ✓ | Daily | 11.1% | 0.55 | -54.8% | 40.8% | 446 | -11.4% |
| 12 | MACD ✓ | Weekly | 10.6% | 0.55 | -65.9% | 61.1% | 72 | -11.8% |
| 13 | Rate of Change ✓ | Weekly | 11.4% | 0.55 | -52.9% | 60.2% | 103 | -11.0% |
| 14 | Stochastic ✓ | Daily | 9.8% | 0.53 | -51.5% | 72.6% | 175 | -12.7% |
✓ = held up out-of-sample. Hypothetical, costs included. See methodology.
For Amphenol (APH), RSI Trend (>50) on the weekly timeframe gave the best balance of return and risk in our test. It still trailed buy-and-hold on raw return — but remember: this is a hypothetical backtest of a standard rule, not a recommendation. Markets change. See the methodology and disclaimer.
More stock
Get the weekly edge report
The best-performing indicator per asset, what changed this week, and the honest caveats — straight to your inbox.